New Research Demonstrates Application of Enzymit's Deep Learning Technology for Novel Biocatalysis Design
21 Aug 2023
Study Reveals Potential for New AI-Based Tools to Transform Enzyme Design, Catalyzing Cell-Free Bioproduction Across Multiple Industries
NESS ZIONA, Israel, Aug. 21, 2023 /PRNewswire/ -- Enzymit, a specialty biochemical company developing cell-free enzymatic manufacturing technology, today announced the publication of a new study published on bioRxiv demonstrating the efficacy of its deep learning-based technology for novel enzyme design.
"The inherent instability of artificial enzymes, combined with production challenges and the limited range of reactions they can facilitate, has restricted their use in real-world applications, while the creation of novel enzymes has proved challenging due to the complex nature of such proteins," said Gideon Lapidoth, PhD, CEO of Enzymit. "This research highlights the role of AI in overcoming the fundamental challenges developing commercially viable enzymes."
The study, Context-Dependent Design of Induced-fit Enzymes using Deep Learning Generates Well Expressed, Thermally Stable and Active Enzymes, proposes an alternative approach to novel enzyme design, by modifying existing enzymes to work with new molecules under a variety of different conditions. This was achieved through the development of two new proprietary AI-based tools, CoSaNN (Conformation Sampling using Neural Network) and SolvIT.
CoSaNN leverages advanced deep learning capabilities to generate new enzyme conformations based on the relationships between an enzyme's genetic sequence and its three-dimensional structure. This ability to redesign the shape of enzymes enabled new chemical reactions unattainable with current design tools. SolvIT, a graph neural network tool, served as a predictive model for protein solubility in the bacterium E. coli and provided an additional layer of optimization for producing highly expressed enzymes.
Combined, the tools enabled the creation of new enzymes with significantly higher thermal stability and exhibiting superior expression levels compared to alternative methods. 54% of the enzyme designs were successfully expressed in E. coli, of which 30% exhibited higher thermal stability than the template enzyme.
"This research demonstrates the transformative potential of artificial intelligence in novel enzyme sequence design, through its ability to capture complex interactions within a protein and to maintain its inherent mechanisms, even when heavily modified," said Prof. Joseph Jacobson, board member and scientific advisor for Enzymit. "Harnessing the power of AI enables us to create vastly more stable enzymes in significantly greater volumes, and at significantly reduced costs for use in a wide range of commercial applications."
About Enzymit
Enzymit is building a cell-free production platform that will make bioproduction faster, simpler, cost-effective, and sustainable. The company leverages complex computational design and deep learning algorithms to create novel enzymes for use in real-world settings. These highly stable and robust enzymes can withstand higher temperatures and work for longer than ever before to enable production of novel molecules in a more efficient and environmentally friendly manner. Enzymit was founded in 2020 by experts in computational protein design, bioengineering, and molecular biology. The company is headquartered in Ness Ziona, Israel.
For more information, please visit: https://enzymit.com/
Follow Enzymit on LinkedIn and Twitter
Media Contact
FINN Partners for Enzymit
Danny Sudwarts
[email protected]
(+1) 469-297-2515
SOURCE Enzymit
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.